Home About MEB Organisation

print this page

policy and special-interest areas

In the Strategic Business Plan for 2009-2013 we identify and discuss five strategic objectives. Our objectives for the next five years are:

  • Clear all assessment backlogs by 2011
  • Continue to develop a scientifically robust, consistent and transparent assessment system
  • Assist and invest in efforts to strengthen the medicinal product regulatory chain, both at national and European level
  • Strengthen scientific underpinning
  • Knowledge must be translated and disseminated.

The MEB special interest areas include:

  • pharmacovigilance
  • central nervous system
  • vaccines
  • female hormones
  • cardiovascular (including diabetes)
  • oncology / haematology

Plans have been set out for each special interest area about the fulfilment thereof:

  • Primarily taking on new reporterships if the relevant indications pertain to the special interest areas.
  • Primarily adopting scientific advice (national), scientific advice (international) and reportership for Paediatric Investigation Plans if the relevant indications pertain to the special interest areas.
  • Finding and maintaining cooperation ties with external experts who are leaders in the field of a special interest area.
  • Signing covenants with expertise centres that are leaders in the field of a special interest area. Progress will be evaluated regularly.
  • Providing optimal support to internal assessors in maintaining their level of scientific knowledge in the field of a special interest area by attending conferences, research, publications, etc.

 

Back